A study of 136 patients with advanced cancers performed by UCSD oncologist and CureMatch co-founder Dr. Razelle Kurzrock and colleagues suggested that combination therapy may be more efficacious than single-drug therapy.
A study performed by UCSD oncologist and CureMatch co-founder Dr. Razelle Kurzrock and colleagues looked at 57 breast cancer patients using next-generation sequencing (NGS), and found that no two were the same. A total of 216 somatic
A multi-year study was performed by UCSD oncologist and CureMatch co-founder Dr. Razelle Kurzrock and colleagues, and looked at 291 patients with advanced cancers, who had received either the standard of care (n = 116) or personalized cancer therapy (n = 175). Patients treated using the standard of care, which was based on their type of cancer, had […]
A personalized approach to cancer therapy leads to improved outcomes in a wide variety of cancers. Personalized cancer therapy correlated with higher response rates, prolonged progression-free survival, and overall survival of cancer patients when compared to non-personalized approaches, in a meta-analysis of more than 330,000 patients enrolled in clinical trials. Schwaederle M, Zhao M, […]
A study was performed of more than 300 patients with diverse refractory cancers, including ovarian cancer, breast cancer, sarcoma, and renal cancer who had undergone next-generation sequencing of their tumor. “Matching Scores” were calculated for each patient based on the number of drug matches and genomic aberrations. It was found that high Matching Scores were […]